Do you want to read an article? Please log in or register.
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting
Gastrointestinal Cancer
Related content
Gastrointestinal Cancer
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
Int J Cancer
Rimini M, Lamarca A, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Vogel A, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Landriscina M, Finkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Formica V, de Sousa Pinto CM, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan SL, Bolnykh I, Lancianese A, Satake T, Bekaii-Saab T, Lavacchi D, Passeri L, Ferrara M, Kang M, Viola MG, Bozzarelli S, Persano M, Masi G, Balsano R, Niger M, Lonardi S, Salani F, Camera S, Ratti F, Fornaro L, Rimassa L, Casadei-Gardini A
doi: 10.1002/ijc.70641
Lung, Respiratory and Thoracic Cancer
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study
Lung Cancer
Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y
doi: 10.1016/j.lungcan.2025.108748
Gastrointestinal Cancer
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population
J Natl Cancer Inst
Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A
doi: 10.1093/jnci/djaf155
Lung, Respiratory and Thoracic Cancer
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
Lung Cancer
Alexander M, Itchins M, Felthun J, Nagrial A, Brown LJ, O'Byrne K, Mersiades AJ, Hughes BGM, Warburton L, Kong BY, Moore M, Blinman P, Bowyer S, Clay T, Spelman T, Pavlakis N, Solomon BJ, Kao S
doi: 10.1016/j.lungcan.2025.108854
Myeloproliferative Neoplasms (MPNs)
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom
Br J Haematol
Rampotas A, Naylor-Layland G, Brown C, Alabdulkarim A, Ryan J, Wadelin F, Alimam S, Tun PWW, Lambert J, O'Sullivan J, Wilson AJ, Tafesh L, McGregor A, Claudiani S, Innes A, Booth E, Leveson J, Knapper S, Garg M, Dubey M, Vatopoulou T, Brierley C, Leung WKN, Greenfield G, McMullin MF, Khan A, Milne K, Brian D, Godfrey A, Harrison CN, Psaila B, Harrington P, Kirkwood A, Somervaille TCP, McLornan DP, UK Blood Cancer Research Network MPN Clinical Study Group
doi: 10.1111/bjh.70511
Genitourinary Cancer
Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Int J Cancer
Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM
doi: 10.1002/ijc.70525
Gastrointestinal Cancer
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial
JAMA Oncol
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW
doi: 10.1001/jamaoncol.2026.2204
ELCC 2026
Lung, Respiratory and Thoracic Cancer
The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR
doi: 10.1016/j.esmoop.2026.106070